Zortix
Sign in
What the podcasts are saying about
MRNA
In-depth coverage
0
Mentions · 7d
7
Mentions · 30d
7
Mentions · 90d
3
Episodes
Latest attributed ideas · most recent first
4 JULMONETARY MATTERS WITH JACK FARLEY · 15:30
Costco and Moderna sentiment gains go unpriced
“The guest argues that Costco and Moderna are undervalued because their positive executive sentiment shifts are not currently reflected in their stock prices.”
In depth · 4/5Verify in source →
4 JULMONETARY MATTERS WITH JACK FARLEY · 00:05
Sentiment mispricing in major equities
“The guest argued that sentiment shifts in Costco, Moderna, and Amazon are not fully priced in, creating potential long and short opportunities.”
Substantive discussion · 3/5Verify in source →
4 JULTHE TIM FERRISS SHOW · 03:45
Platform therapeutics will revolutionize drug development
“The guest argued that transitioning from single-asset drug development to platform therapeutics—building a common technological infrastructure for multiple medicines—will radically de-risk and accelerate future drug pipelines.”
Core thesis · 5/5Verify in source →
4 JULTHE TIM FERRISS SHOW · 03:30
Targeted platforms outperform universal mRNA delivery
“The guest argued that the universal mRNA platform model is structurally flawed, requiring developers to instead build distinct, tissue-specific delivery platforms sequentially.”
In depth · 4/5Verify in source →
4 JULCNBC FAST MONEY · 01:15
Patent cliffs trigger biotech M&A wave
“Large pharmaceutical companies are expected to acquire small-to-mid-cap biotech firms to replace an estimated $275 billion in revenue threatened by upcoming patent expirations.”
In depth · 4/5Verify in source →
4 JULCNBC FAST MONEY · 09:40
M&A and clinical catalysts revive biotech
“The biotech sector is experiencing a significant rally driven by major M&A activity, corporate investments, and upcoming clinical trial data.”
Substantive discussion · 3/5Verify in source →
4 JULCNBC FAST MONEY · 02:10
Diversified healthcare over high-flying biotech
“The thesis presented suggests favoring diversified healthcare ETFs over individual high-flying biotech stocks that have already experienced massive run-ups.”
Substantive discussion · 3/5Verify in source →
The weekly signal

Get a weekly digest of what podcasts said about your watchlist.

Pick a few tickers. Once a week we send the most-discussed ideas across finance podcasts — attributed, with a link to verify. No noise, no advice.

Double opt-in: we’ll email you to confirm before anything else. We store your email and chosen tickers only to send this digest — nothing else, never shared.

Related tickers
NVDAMSFTGOOGLAMZNMETAAAPLMSTRSPYMUTSLACRMCOIN
Browse all tickers →This week’s signal →
MENTIONS & DEPTH REFLECT PODCAST DISCUSSION VOLUME · NOT A RATING, FORECAST, OR RECOMMENDATION